Tenderwize
Retour à la recherche

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 369 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of pharmaceutical product Eculizumab including indications gMG and NMOSD
  • Conclusion of discount contracts under §130a Abs. 8 SGB V
Afficher le résumé complet

Open-House procedure for discount contracts (Rabattverträge) according to § 130a Abs. 8 SGB V for the active substance Eculizumab including indications generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). The procedure is open to all qualified pharmaceutical entrepreneurs. Contracts have a fixed maximum duration until 31 August 2027, with possible start from 1 April 2026. No estimated value is provided. The tender is not a public procurement under EU directives; it is an Open-House model with no negotiation. Submission is possible at any time until the contract end.

Risques

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG
  • Registered office in Germany, EU, or EEA
  • Valid marketing authorization for the product or entitlement to market

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Conclusion of drug discount contracts for Eculizumab (including gMG and NMOSD) under an Open-House procedure. All qualified pharmaceutical entrepreneurs can join at any time during the contract period.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Mar 2026 - Aug 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable.

Date limite

Deadline Aug 30, 2027

Détails de la procédure

Date de publication
24 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
133422-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3